Versant ventures collaborates with abcellera to accelerate drug development for its portfolio of biotech companies

Vancouver, british columbia & san francisco--(business wire)---- $abcl--abcellera (nasdaq: abcl) and versant ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by versant's portfolio of biologics-focused biotechs. versant and abcellera already have enabled three of the firm's stealth-stage companies under previous partnerships. under the terms of the deal, versant portfolio companies will have rights to develop and commercialize the result
ABCL Ratings Summary
ABCL Quant Ranking